The study found that patients who received the drug in combination with other treatments including steroids and remdesivir had a 54% greater relative likelihood of survival without the need for mechanical ventilation compared with patients receiving placebo and other treatments.

Humanigen plans to submit an emergency use authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for lenzilumab.

Humanigen awarded 2 patents against immunotherapy toxicities
The U.S. Patent and Trademark Office has awarded Humanigen two patents for the use of lenzilumab.

Humanigen, Avid enter COVID-19 therapy manufacturing agreement
Contract development and manufacturing organization Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production...

Ajinomoto to up production of Humanigen's COVID-19 drug
Ajinomoto Bio-Pharma Services and Humanigen are expanding their manufacturing agreement for the fill-finish supply of lenzilumab, an investigational COVID-19...

Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...

Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...